SCHEMBL2476501

SCHEMBL2476501

CCNc1c(F)c(F)c2c(c1F)C(=O)N(c1c(C(C)C)cccc1C(C)C)C2=O

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ANPEP P15144 6/20 0.59
DPP4 P27487 6/20 0.59
NR1H2 P55055 1/20 0.40
NR1H3 Q13133 1/20 0.40
MEN1 O00255 4/20 0.33
KMT2A Q03164 4/20 0.33
USP2 O75604 2/20 0.33
CASP1 P29466 2/20 0.33
BRCA1 P38398 2/20 0.33
CASP7 P55210 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
LMNA P02545 1/20 0.33
MAPT P10636 1/20 0.33
HTT P42858 1/20 0.33
RECQL P46063 1/20 0.33
YWHAG P61981 1/20 0.33
HBB P68871 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
MAP3K5 Q99683 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2477491 0.94 ANPEP (0.61) ANPEPDPP4NR1H2NR1H3MEN1
SCHEMBL2477212 0.86 ANPEP (0.55) ANPEPDPP4NR1H2NR1H3
SCHEMBL2480594 0.86 ANPEP (0.55) ANPEPDPP4NR1H2NR1H3MEN1
SCHEMBL2481189 0.83 DPP4 (0.80) ANPEPDPP4NR1H2NR1H3LMNA
SCHEMBL2477514 0.81 ANPEP (0.58) ANPEPDPP4NR1H2NR1H3MEN1
SCHEMBL11910731 0.81 ANPEP (0.49) ANPEPDPP4MEN1KMT2AMAPT
SCHEMBL2479315 0.81 ANPEP (0.57) ANPEPDPP4NR1H2NR1H3MEN1
SCHEMBL2989683 0.79 ANPEP (0.55) ANPEPDPP4NR1H2NR1H3MEN1
SCHEMBL17531038 0.79 DPP4 (0.68) ANPEPDPP4NR1H2NR1H3LMNA
SCHEMBL11888788 0.78 ANPEP (0.46) ANPEPDPP4MEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232299-B2 Phthalimide derivatives that influence cellular vesicular systems, pharmaceutical compositions, and use thereof AVIDIN KFT. (HU) 2012-07-31 US claimed
EP-2373618-A2 PHTHALIMIDE DERIVATIVES THAT INFLUENCE CELLULAR VESICULAR SYSTEMS, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF Avidin KFT (HU) 2011-10-12 EP claimed
US-20100184762-A1 PHTHALIMIDE DERIVATIVES THAT INFLUENCE CELLULAR VESICULAR SYSTEMS, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF AVIDIN KFT (HU) 2010-07-22 US claimed
WO-2008155593-A2 PHTHALIMIDE DERIVATIVES FOR LABELING LIPID DROPLETS, AND A METHOD FOR VISUALIZATION OF CELLS AND/OR CELLULAR ORGANELLES AVICOR KUTATO (HU) 2008-12-24 WO claimed
WO-2008155594-A2 PHTHALIMIDE DERIVATIVES THAT INFLUENCE CELLULAR VESICULAR SYSTEMS, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF AVIDIN KFT (HU) 2008-12-24 WO claimed
US-8232299-B2 Phthalimide derivatives that influence cellular vesicular systems, pharmaceutical compositions, and use thereof AVIDIN KFT. (HU) 2012-07-31 US disclosed
US-8232299-B2 Phthalimide derivatives that influence cellular vesicular systems, pharmaceutical compositions, and use thereof AVIDIN KFT. (HU) 2012-07-31 US disclosed
US-8232299-B2 Phthalimide derivatives that influence cellular vesicular systems, pharmaceutical compositions, and use thereof AVIDIN KFT. (HU) 2012-07-31 US disclosed
EP-2373618-A2 PHTHALIMIDE DERIVATIVES THAT INFLUENCE CELLULAR VESICULAR SYSTEMS, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF Avidin KFT (HU) 2011-10-12 EP disclosed
US-20100184762-A1 PHTHALIMIDE DERIVATIVES THAT INFLUENCE CELLULAR VESICULAR SYSTEMS, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF AVIDIN KFT (HU) 2010-07-22 US disclosed
US-20100184762-A1 PHTHALIMIDE DERIVATIVES THAT INFLUENCE CELLULAR VESICULAR SYSTEMS, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF AVIDIN KFT (HU) 2010-07-22 US disclosed
US-20100184762-A1 PHTHALIMIDE DERIVATIVES THAT INFLUENCE CELLULAR VESICULAR SYSTEMS, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF AVIDIN KFT (HU) 2010-07-22 US disclosed
WO-2008155593-A2 PHTHALIMIDE DERIVATIVES FOR LABELING LIPID DROPLETS, AND A METHOD FOR VISUALIZATION OF CELLS AND/OR CELLULAR ORGANELLES AVICOR KUTATO (HU) 2008-12-24 WO disclosed
WO-2008155594-A2 PHTHALIMIDE DERIVATIVES THAT INFLUENCE CELLULAR VESICULAR SYSTEMS, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF AVIDIN KFT (HU) 2008-12-24 WO disclosed
WO-2008155594-A2 PHTHALIMIDE DERIVATIVES THAT INFLUENCE CELLULAR VESICULAR SYSTEMS, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF AVIDIN KFT (HU) 2008-12-24 WO disclosed
WO-2008155593-A2 PHTHALIMIDE DERIVATIVES FOR LABELING LIPID DROPLETS, AND A METHOD FOR VISUALIZATION OF CELLS AND/OR CELLULAR ORGANELLES AVICOR KUTATO (HU) 2008-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100184762-A1 PHTHALIMIDE DERIVATIVES THAT INFLUENCE CELLULAR VESICULAR SYSTEMS, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF NSFL1C, LIPC, NPC1L1 ANPEP 4444/4885DPP4 3452/4885NR1H2 68/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.